The market is myopically focused on the transient post-pandemic decline in Abbott's diagnostics revenue, failing to appreciate the robust, diversified growth engines in its medical devices, nutrition, and established pharmaceuticals segments. This temporary headwind offers an opportunity to acquire a high-quality, defensive healthcare innovator at a discount.
Bear
$90
-13%
20%
Base
$130
+26%
50%
Bull
$155
+51%
30%
Catalysts
Accelerated growth in core medical devices and nutrition segments
Successful new product launches and pipeline advancements (e.g., FreeStyle Libre)
Improved clarity and stability in global supply chains and healthcare spending
Risk Factors
Sustained weakness in diagnostics revenue beyond current expectations
Increased competitive pressures in key medical device or nutrition markets
Unfavorable regulatory changes or product recalls impacting major revenue streams
Key Debates
P/E expands to 25x by Q4 on sustained 8% growth.
Net Margin expands 200bps by Q3 from operational efficiencies.
Low D/E triggers M&A, boosting ROE to 15% by H1.
Recent Daily Analysis
— Abbott's failure to rally despite a rating upgrade and near-oversold RSI of 35 signals a deeply entrenched, and we believe flawed, market thesis. We hypothesize that consensus models are incorrectly assuming a zero-sum game where GLP-1 drug adoption directly cannibalizes sales of the Freestyle Libre glucose monitor. The real-world mechanism is a complementary one: GLP-1 users become more engaged with their metabolic health, driving higher, not lower, monitoring adherence and device usage. This fear has created a rare mispricing in a high-quality name. If upcoming earnings show Libre sales growth remaining above 20% year-over-year, it will directly falsify the market's core fear, forcing a rapid repricing toward our +33% DCF value.